Based on the XTL Biopharmaceuticals Ltd ADR stock forecast from 0 analysts, the average analyst target price for XTL Biopharmaceuticals Ltd ADR is not available over the next 12 months. XTL Biopharmaceuticals Ltd ADR’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of XTL Biopharmaceuticals Ltd ADR is Slightly Bearish, which is based on 3 positive signals and 6 negative signals. At the last closing, XTL Biopharmaceuticals Ltd ADR’s stock price was USD 2.42. XTL Biopharmaceuticals Ltd ADR’s stock price has changed by -0.82% over the past week, -13.88% over the past month and +116.07% over the last year.
Analyst Ratings
Target Price Action
Rating Action
Analyst
Rating
Price
Date
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Add to Watchlists
loading..
Download Confirmation
Premium customers can only download records visible on the current page view, while Platinum customers can download the first 1000 records.
Paid-only feature
CSV downloads are only available for paying customers.
Thank you for Sharing your Stock Targets for XTLB !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
